Treponema pallidum Antibodies: What Non-Reactive and Reactive Mean

Sample type: Serum

Other names: T pallidum Antibodies, Treponema pallidum Ab, T pallidum Ab, Treponemal Antibody, Treponemal Ab Screen, T pallidum Total Antibodies, Treponema pallidum IgG IgM, Syphilis Treponemal Antibody

Non Reactive

No antibodies to Treponema pallidum were detected in this sample. What that settles depends on timing. Antibodies take time to appear — up to about two weeks after primary infection — so a test taken soon after a possible exposure can be non-reactive in someone who is infected, and the CDC's treatment guidelines state that using only one type of serologic test is insufficient for diagnosis and can be falsely negative in someone tested during primary syphilis. Sensitivity in primary syphilis also differs by assay: the CDC reports 78.2% for FTA-ABS and 94.5% for TPPA. If you had sexual contact in the 90 days before a partner was diagnosed with primary, secondary or early latent syphilis, the guidelines advise treating you presumptively even when your own serology is negative — ask the clinician who ordered this test. A non-reactive result is not immunity and does not protect against future infection.

Reactive

Antibodies to Treponema pallidum were found. That is consistent with exposure at some point, but a single reactive screen is not confirmation on its own; it does not say when, and it does not establish that an infection is active now. Treponemal antibodies typically persist for life despite treatment. Reversion after treatment in primary syphilis is reported for some older assays, and the CDC says no published data exist on whether it happens with the immunoassays many laboratories now use — which is why these tests cannot be used to monitor response to therapy. A reactive screen is also frequently not confirmed: in a CDC series of 140,176 specimens, 56.7% of reactive screens were non-reactive on RPR, and 31.6% of those were non-reactive on a second treponemal test as well. The next step is the non-treponemal test and, where the two disagree, a second treponemal assay such as TPPA. This result is the beginning of the testing, not the end of it.

At a Glance

This is a treponemal test: it looks for antibodies your immune system makes against Treponema pallidum, the bacterium that causes syphilis. It is reported reactive or non-reactive rather than as a number, which is why there is no reference range here.

Two things decide what either result means, and neither is the word on the report:

  • When you were exposed. Antibodies take time to appear. The CDC states they "might take up to 2 weeks after primary infection", and treponemal tests can miss early disease.
  • What the other syphilis test showed. A reactive treponemal test is not read alone: the CDC says the two types of test are used in combination when the primary test is reactive, and the pair is what carries the meaning.

How to read your result

The result is one of two words, and what each means is decided outside the word itself — by when any possible exposure happened and what the non-treponemal test showed. The rest of this page takes the two in turn, non-reactive first.

What a non-reactive result means

No antibodies to Treponema pallidum were detected in this sample. What that settles depends on timing, and the CDC's guidelines are explicit that one test is not the whole answer: "Use of only one type of serologic test (nontreponemal or treponemal) is insufficient for diagnosis" — an approach that "can result in false-negative results among persons tested during primary syphilis".

Antibodies need time to develop. The CDC states they "might take up to 2 weeks after primary infection" to appear, so a test soon after a possible exposure can be non-reactive in someone genuinely infected.

How much a treponemal test misses in early infection depends on the assay. The CDC reports estimated sensitivity in primary syphilis of 78.2% for FTA-ABS and 94.5% for TPPA. This record does not capture which assay produced your result — the laboratory report does.

A recent exposure can outrank the result altogether. If you had sexual contact in the 90 days before a partner was diagnosed with primary, secondary or early latent syphilis, the CDC's guidelines say you "should be treated presumptively for early syphilis, even if serologic test results are negative". The clock runs backwards from the partner's diagnosis, not forwards from it, and a non-reactive result does not end that conversation on its own. This is a question for your clinician, who has the dates.

So the same word means two things. With no recent possible exposure it is straightforward evidence against syphilis; with one it may simply be too early, and the exposure history and the clinician decide what happens next.

It also says nothing about the future. It is a statement about antibodies in one sample on one day: not immunity, not protection.

What a reactive result means

A reactive result means treponemal antibodies were found. On its own it does not mean you have an active infection now.

Treponemal antibodies usually stay for life. The CDC states they "typically persist for life despite treatment".

The often-quoted reversion rate does not describe every test. The estimate that 15%–25% of people treated in primary syphilis revert within 2–3 years is reported for FTA-ABS and MHA-TP specifically, and in those studies no one treated at a later stage seroreverted. The CDC separately reports seroreversion in advanced HIV disease, and says no published data exist on reversion after treatment with the EIA and CIA immunoassays many laboratories now use. Since this record does not capture which assay was run, that percentage may not describe your test at all.

So persistence is the expectation and the exceptions are assay-specific — which is why the CDC states that treponemal tests "cannot be used to monitor response to therapy" and that "treponemal antibody titers do not predict treatment response".

So a reactive test cannot distinguish a current infection from one treated years ago — the point a 2011 Journal of Infectious Diseases editorial makes.

And a reactive screen is often not confirmed. Of 140,176 specimens screened across five CDC laboratories, 4,834 were reactive (3.4%); 2,743 of those (56.7%) were non-reactive on RPR; and 866 of those (31.6%) were non-reactive on a second treponemal test too, which the CDC says suggests a false positive.

A 2016 series of 10,060 patients found the same shape, at 1.0% false-reactive across everyone tested.

What follows is procedural, not frightening: a reactive screen is the beginning of the testing, not the end of it.

The two testing algorithms

A treponemal result sits inside a sequence. The CDC describes two.

  starts with then
Traditional a non-treponemal test (RPR or VDRL) reactive specimens are confirmed with a treponemal test
Reverse sequence a treponemal immunoassay a reactive result "must be followed by a quantitative nontreponemal test"

This test is the treponemal half: under the reverse sequence it ran first, and a reactive result sends you to an RPR or VDRL; under the traditional algorithm it confirmed an already-reactive one.

When the two disagree, a second treponemal assay is the next step — not the last word. For a reactive screen with a non-reactive RPR, the CDC recommends a test "using a different type of treponemal test assay and target (e.g., TPPA)". In its discordance report, sera with a reactive TP-PA "are considered to have past or present syphilis"; where TP-PA is non-reactive, "syphilis is unlikely". Even then serology is one input: only one type of test is insufficient for diagnosis, and history and examination are part of the conclusion.

If you remember only one thing

A non-reactive result is reassuring unless the exposure was recent, in which case it is too early to be reassuring. Antibodies take up to about two weeks to appear after primary infection, and one type of serologic test is insufficient on its own — if you had sexual contact in the 90 days before a partner's diagnosis of early syphilis, you may be treated presumptively despite a negative result. If yours is reactive, the thing to know is that treponemal antibodies usually stay for life, so the test cannot by itself tell you whether an infection is current.

Two people, same result

Two people both have a non-reactive Treponema pallidum antibody result.

The first was tested in routine screening with no particular exposure in mind. For her the result is what it looks like: evidence against syphilis, read alongside the rest of the panel.

The second was tested five days after a possible exposure. Same word, much less information. Antibodies might take up to two weeks to appear, so a test at five days can be non-reactive in someone infected. His exposure history decides what happens next — and if his contact fell in the 90 days before a partner's diagnosis of early syphilis, the guidelines say to treat him presumptively whatever the serology shows.

Nothing in the result distinguishes them. The timing does, and only the person tested and their clinician know it.

What this result cannot tell you

It cannot tell you when. A reactive result carries no date: because the antibodies usually persist, it looks the same whether the infection was last year or two decades ago and treated.

It cannot tell you whether an infection is active — and the other test does not settle that alone either. Non-treponemal titres "might correlate with disease activity" and are what the CDC uses to monitor treatment response, read with history and examination. A non-reactive RPR does not exclude untreated infection: either type of test can be falsely negative in primary syphilis.

It cannot stage the infection. Primary, secondary, latent and tertiary syphilis are distinctions a clinician makes, not readings off one antibody test.

It cannot exclude very recent infection when it is non-reactive — the limitation this page leads with.

It is not a test of immunity. Antibodies do not protect against reinfection, and a non-reactive result does not mean you are protected either.

Common interpretation mistakes

Reading "non-reactive" as "cleared" after a recent exposure. The CDC's guidelines say one type of serologic test is insufficient for diagnosis and can be falsely negative in someone tested during primary syphilis.

Reading "reactive" as "I have syphilis now." More than half of reactive screens in the CDC series were non-reactive on RPR, and about a third of those did not confirm.

Expecting the result to change after treatment. It usually does not, and where reversion is reported it is assay-specific.

Using this test to check whether treatment worked. The CDC states plainly that treponemal tests cannot be used for that.

Reading a reactive result without the other syphilis test. Once a screen is reactive the pair is the unit of meaning, in either algorithm.

Assuming all treponemal tests perform alike. Sensitivity in primary syphilis differs substantially between assays, and so does what is known about reversion.

Questions your doctor may ask

Was there a specific possible exposure, and how long before the test? Has a partner been diagnosed, and when relative to your last contact? Have you ever been treated for syphilis? What did the RPR or VDRL show, and was there a titre? Which treponemal test did the laboratory run? Are you pregnant, or planning to be? Any symptoms now, or any you dismissed?

Read together with

RPR and VDRL are the non-treponemal tests a reactive result is read with, because one type of serologic test is insufficient for diagnosis on its own. They carry the titre, which the CDC uses to monitor treatment response and which "might correlate with disease activity" — alongside history and examination, not instead of them.

The syphilis screening panel covers the reflex sequence some laboratories order as one test.

Clinical pearls

Treponemal, not non-treponemal: antibodies to the organism, not the lipoidal antibodies RPR and VDRL measure.

Antibodies might take up to 2 weeks after primary infection to appear; a non-reactive result soon after a possible exposure does not exclude primary syphilis.

One type of serologic test is insufficient for diagnosis; a patient who had sexual contact in the 90 days before a partner's diagnosis of primary, secondary or early latent syphilis is treated presumptively whatever their own serology shows.

Treponemal antibodies typically persist for life despite treatment; the 15–25% primary-stage reversion estimate is reported for FTA-ABS and MHA-TP, with no published data for EIA or CIA.

Treponemal tests cannot monitor response to therapy; non-treponemal titres are used for that and "might correlate with disease activity".

In the CDC's five-laboratory series, 56.7% of reactive screens were RPR-non-reactive and 31.6% of those did not confirm.

Discordant results are adjudicated with a second, different treponemal assay such as TPPA — which resolves the laboratory question, not the clinical one.

Clinical Takeaway

A treponemal assay reported as reactive or non-reactive, with no numeric range. A non-reactive result does not exclude early infection: antibodies "might take up to 2 weeks after primary infection", estimated sensitivity in primary syphilis is 78.2% for FTA-ABS and 94.5% for TPPA, and "use of only one type of serologic test (nontreponemal or treponemal) is insufficient for diagnosis". A patient whose sexual contact fell in the 90 days before a partner's diagnosis of early syphilis is treated presumptively regardless of their own serology. A reactive result is consistent with exposure but establishes neither timing nor activity, and a single screen is not confirmation: antibodies "typically persist for life despite treatment", reversion is reported only for some assays, and treponemal tests "cannot be used to monitor response to therapy". Reactive screens are frequently unconfirmed — in a 140,176-specimen CDC series 56.7% of reactive screens were RPR-non-reactive and 31.6% of those failed a second treponemal assay, with 1.0% false-reactive overall in a 2016 series. The result belongs inside one of the two CDC algorithms and with the clinician who ordered it.

In one sentence

The treponemal half of syphilis testing — reactive means antibodies, usually for life; non-reactive means none found today, which is not the same as none at all if the exposure was recent, because antibodies can take up to two weeks to appear and your clinician reads the result against that timing.

Bottom line

Non-reactive with no recent exposure is straightforward evidence against syphilis. Non-reactive after a recent exposure may be too early — one serologic test is insufficient on its own, and contact in the 90 days before a partner's diagnosis of early syphilis can mean treatment for you regardless of the result. Reactive is consistent with exposure at some point — not when, not whether it is active, not confirmed by this test alone — and the next tests, read with your history, answer those. Either way the result belongs with the clinician who ordered it.

Treponema pallidum Antibodies
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Treponema pallidum Antibodies — 10,000+ markers explained
One Treponema pallidum Antibodies result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time

Frequently Asked Questions

What does a non-reactive Treponema pallidum antibody result mean?
It means no antibodies to Treponema pallidum, the bacterium that causes syphilis, were detected in that sample. How much that settles depends on timing. Antibodies take time to develop, and the CDC states they might take up to two weeks after primary infection to appear, so a test taken soon after a possible exposure can be non-reactive in someone who is genuinely infected. The CDC's treatment guidelines are explicit that using only one type of serologic test is insufficient for diagnosis and can produce false-negative results in people tested during primary syphilis. So the same word means something quite different depending on whether there was a possible exposure in the days before the test. With no recent exposure, a non-reactive result is straightforward evidence against syphilis; with one, the exposure history rather than this result decides what happens next.
I was exposed recently and my test is non-reactive. Am I in the clear?
Not necessarily, and this is the situation the CDC's guidelines single out. Antibodies take time to appear — up to about two weeks after primary infection — so a test done soon after a possible exposure can be non-reactive in someone who is genuinely infected, and the CDC states that using only one type of serologic test is insufficient for diagnosis and can be falsely negative during primary syphilis. How much a treponemal test misses in early infection also depends on the assay: the CDC reports estimated sensitivity in primary syphilis of 78.2% for FTA-ABS and 94.5% for TPPA. In one situation the guidelines go further than retesting: if you had sexual contact in the 90 days before a partner was diagnosed with primary, secondary or early latent syphilis, you should be treated presumptively for early syphilis even if your tests are negative. Note the direction — the window is counted backwards from the partner's diagnosis to your contact, not forwards from the diagnosis to today. So tell the clinician who ordered the test when the possible exposure was and what is known about the partner: that history, not this result, decides what happens next.
What does a reactive result mean? Do I have syphilis?
A reactive result means treponemal antibodies were found, which is consistent with exposure to Treponema pallidum at some point. A single reactive screen is not confirmation on its own, it does not say when, and it does not establish that an infection is active. Two things explain why. First, these antibodies typically persist for life despite treatment, so a reactive test looks the same whether an infection was treated twenty years ago or is present now. Second, reactive screens are often not confirmed: in a CDC series of 140,176 specimens, 4,834 screened reactive, 56.7% of those were non-reactive on RPR, and 31.6% of those were non-reactive on a second treponemal test too. A reactive result is the start of the testing sequence rather than a diagnosis, and what it means for you is a conversation with the clinician who ordered it.
Why is this test done alongside an RPR or VDRL?
Because the two kinds of test answer different questions, and the CDC says they are used in combination when the primary test is reactive. This is a treponemal test: it detects antibodies against the bacterium itself, which usually persist for life. RPR and VDRL are non-treponemal tests, and they produce a titre that "might correlate with disease activity" and is used to monitor treatment response. One is evidence that the immune system has encountered the organism — evidence rather than proof, given how often a reactive screen is not confirmed; the other is what a clinician follows over time. The CDC describes two sequences for combining them. The traditional algorithm starts with a non-treponemal test and confirms reactive specimens with a treponemal one. The reverse sequence algorithm starts with a treponemal immunoassay, and a reactive result must be followed by a quantitative non-treponemal test. Which order your laboratory used determines what your result is doing in the sequence.
My treponemal test is reactive but my RPR is non-reactive. What does that mean?
This combination is common and it has a defined next step rather than an immediate meaning. The CDC recommends that a reactive treponemal screen with a non-reactive non-treponemal test be adjudicated with an additional treponemal test using a different assay and target, such as TPPA. If that second test is reactive, the CDC's report says the person is considered to have past or present syphilis. If it is non-reactive, the report says syphilis is unlikely and that this suggests the initial screen was a false positive. Serology is still not the whole answer — the guidelines state that one type of serologic test is insufficient for diagnosis, so history and examination are part of the conclusion. The proportions are worth knowing: in the CDC's five-laboratory series, 2,743 of 4,834 reactive screens were RPR-non-reactive, and 866 of those did not confirm. A 2016 study in the American Journal of Clinical Pathology found a similar pattern, with 29.3% of discordant samples non-reactive on TP-PA.
Will this test ever go back to non-reactive after treatment?
Usually not. The CDC states that treponemal antibodies typically persist for life despite treatment. Reversion is reported after very early treatment, but the figure usually quoted — 15% to 25% reverting within two to three years — comes from studies of FTA-ABS and MHA-TP, and in those studies no one treated at a later stage seroreverted. The CDC says no published data exist on whether reversion happens with the EIA and CIA immunoassays many laboratories now use, so if that is what your laboratory ran, the honest answer is that it is not known. A result that stays reactive is sometimes described as a scar in the blood rather than a sign of ongoing infection. This is also the reason the CDC states that treponemal tests cannot be used to monitor response to therapy. Whether treatment worked is judged on the non-treponemal titre, together with history, examination and risk assessment, rather than on whether this test turns negative.
What is the difference between a treponemal and a non-treponemal test?
A treponemal test, like this one, detects antibodies directed at Treponema pallidum itself. Those antibodies usually appear early and usually stay for life, so the test is good at answering whether the immune system has ever encountered the organism and poor at answering whether an infection is active. A non-treponemal test, RPR or VDRL, detects antibodies against lipoidal material released during infection, and it is reported as a titre that "might correlate with disease activity" and is used to monitor treatment response. Neither is a complete answer by itself, and a non-reactive RPR does not rule out untreated infection. The CDC's testing algorithms exist precisely to combine them, in one order or the other, and a discordant pair is resolved with a second treponemal assay such as TPPA rather than by preferring one of the first two.
Does a non-reactive result mean I am immune or protected?
No. A non-reactive result means no treponemal antibodies were detected in that sample on that day. It is not a statement about immunity, and there is no protective immunity to syphilis to measure — having had the infection before does not prevent getting it again, and neither does never having had it. A reactive result is not protection either; it indicates that antibodies are present, not that they will prevent a future infection. Anyone who may be exposed again, and who wants to know their status after that, needs testing again after enough time has passed for antibodies to develop. What counts as enough time, and whether to test at all, is a question for the clinician who ordered this one.
Which treponemal test was used, and does it matter?
It can matter, and this record does not capture it — the laboratory report does. Treponemal tests include enzyme and chemiluminescence immunoassays, TPPA, and FTA-ABS, and they do not perform identically. For primary syphilis the CDC reports estimated sensitivity of 78.2% for FTA-ABS and 94.5% for TPPA, citing a 2019 study, so the chance of missing a very early infection is not the same across assays. Assay also matters when results disagree: the CDC's advice for a discordant pair is specifically to use a different type of treponemal assay and target, such as TPPA, rather than repeating the same one. If the timing of a possible exposure matters in your case, the assay name on the report is worth knowing and worth asking about.
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024
    Centers for Disease Control and Prevention, MMWR Recommendations and Reports · 2024 View source ↗
  2. Discordant Results from Reverse Sequence Syphilis Screening — Five Laboratories, United States, 2006–2010
    Centers for Disease Control and Prevention, MMWR · 2011 View source ↗
  3. Performance Characteristics of the Reverse Syphilis Screening Algorithm in a Population With a Moderately High Prevalence of Syphilis
    American Journal of Clinical Pathology · 2016 View source ↗
  4. Serodiagnosis of Syphilis in the Recombinant Era: Reversal of Fortune
    The Journal of Infectious Diseases · 2011 View source ↗
  5. Syphilis — Sexually Transmitted Infections Treatment Guidelines, 2021
    Centers for Disease Control and Prevention · 2021 View source ↗
Article Review Log
Last reviewed October 19, 2026
Originally published October 19, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro